CN1829806A - 产生高亲和力抗体的方法 - Google Patents

产生高亲和力抗体的方法 Download PDF

Info

Publication number
CN1829806A
CN1829806A CNA2004800082701A CN200480008270A CN1829806A CN 1829806 A CN1829806 A CN 1829806A CN A2004800082701 A CNA2004800082701 A CN A2004800082701A CN 200480008270 A CN200480008270 A CN 200480008270A CN 1829806 A CN1829806 A CN 1829806A
Authority
CN
China
Prior art keywords
ser
antibody
thr
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800082701A
Other languages
English (en)
Chinese (zh)
Inventor
桑贾耶·辛格
凯瑟琳·福斯特
赫伦·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of CN1829806A publication Critical patent/CN1829806A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2004800082701A 2003-02-01 2004-02-02 产生高亲和力抗体的方法 Pending CN1829806A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44422903P 2003-02-01 2003-02-01
US60/444,229 2003-02-01

Publications (1)

Publication Number Publication Date
CN1829806A true CN1829806A (zh) 2006-09-06

Family

ID=32850839

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2004800082701A Pending CN1829806A (zh) 2003-02-01 2004-02-02 产生高亲和力抗体的方法
CN201210316908.4A Expired - Lifetime CN102993306B (zh) 2003-02-01 2004-02-02 高亲和力抗人类IgE抗体
CN2004800070117A Expired - Lifetime CN1771338B (zh) 2003-02-01 2004-02-02 高亲和力抗人类IgE抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201210316908.4A Expired - Lifetime CN102993306B (zh) 2003-02-01 2004-02-02 高亲和力抗人类IgE抗体
CN2004800070117A Expired - Lifetime CN1771338B (zh) 2003-02-01 2004-02-02 高亲和力抗人类IgE抗体

Country Status (15)

Country Link
US (4) US7531169B2 (https=)
EP (4) EP2000481B1 (https=)
JP (4) JP2006516408A (https=)
CN (3) CN1829806A (https=)
AU (3) AU2004209637A1 (https=)
CA (2) CA2514840C (https=)
CY (2) CY1118063T1 (https=)
DK (2) DK2407485T3 (https=)
ES (2) ES2575547T3 (https=)
HU (2) HUE028407T2 (https=)
IL (1) IL176940A (https=)
MX (1) MX338940B (https=)
PT (1) PT2000481E (https=)
SI (2) SI2000481T1 (https=)
WO (2) WO2004070011A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
CN109651510A (zh) * 2018-12-04 2019-04-19 上海嘉霈医药科技有限公司 抗Eno1抗体及其用途

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004070011A2 (en) * 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
CN102702359A (zh) * 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006055704A2 (en) * 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
DE102007052281A1 (de) * 2007-11-02 2009-05-07 Zenteris Gmbh Einschritt-Multiplex-Immuntest
US20100248971A1 (en) 2007-12-03 2010-09-30 Takashi Inagaki Process for antibody production
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
BRPI0918670B8 (pt) 2008-09-17 2021-05-25 Xencor Inc anticorpo
EP2427497B1 (fr) 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
KR101832510B1 (ko) 2009-10-26 2018-02-26 제넨테크, 인크. 치료 항-ｉｇｅ 항체에 대해 특이적인 항체를 검출하기 위한 검정 및 아나필락시스에서의 이의 용도
KR20130010123A (ko) * 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10196458B2 (en) 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
EP3100048B1 (en) 2014-01-29 2021-05-05 Cytiva Sweden AB Method and system for interaction analysis
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
ES2857553T3 (es) * 2014-10-24 2021-09-29 Hoffmann La Roche Humanización de anticuerpos basada en ángulo interdominio VH-VL
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
AU2018205484B2 (en) * 2017-01-06 2024-11-21 Sixal, Inc. Therapeutic anti-lgE antibodies and methods and compositions thereof
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
US20210115155A1 (en) * 2018-03-26 2021-04-22 Novartis Ag Methods of treating chronic spontaneous urticaria using ligelizumab
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
WO2021255621A1 (en) 2020-06-15 2021-12-23 Novartis Ag Treatment of food allergy using anti-ige antibodies
EP4305190A4 (en) 2021-03-11 2025-03-26 Iggenix, Inc. METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION
CN117460531A (zh) 2021-06-14 2024-01-26 诺华股份有限公司 含有抗IgE抗体的药物配制品
EP4431528A1 (en) * 2021-10-29 2024-09-18 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
KR20240116810A (ko) 2021-12-14 2024-07-30 노파르티스 아게 항-ige 항체를 사용한 알레르기 반응의 치료
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN116359516A (zh) * 2023-04-04 2023-06-30 郑州安图生物工程股份有限公司 检测血清总IgE含量的试剂盒及应用
CN119490594B (zh) * 2023-08-15 2025-09-16 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用
CN119745868B (zh) * 2024-11-21 2026-04-07 广州创瑞健康科技有限公司 一种人免疫球蛋白e拮抗剂、筛选方法以及应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268176A (en) * 1916-11-29 1918-06-04 Us Slicing Machine Co Power mechanism for slicing-machines.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5428133A (en) 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
AU618317B2 (en) 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
ES2219640T3 (es) * 1992-09-24 2004-12-01 Novartis Ag Anticuerpos monoclonales reformados contra un isotopo de inmunoglobulina.
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
CN1289253A (zh) * 1998-01-29 2001-03-28 泰诺士公司 以lgE拮抗剂治疗特应性皮炎
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US20060234296A1 (en) 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
WO2004070011A2 (en) * 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
CN109651510A (zh) * 2018-12-04 2019-04-19 上海嘉霈医药科技有限公司 抗Eno1抗体及其用途
CN109651510B (zh) * 2018-12-04 2023-03-24 上海长征医院 抗Eno1抗体及其用途

Also Published As

Publication number Publication date
WO2004070010A3 (en) 2005-12-08
JP2011217747A (ja) 2011-11-04
HK1166330A1 (en) 2012-10-26
SI2407485T1 (sl) 2016-09-30
IL176940A0 (en) 2006-12-10
EP2407485A1 (en) 2012-01-18
US8252284B2 (en) 2012-08-28
US8604171B2 (en) 2013-12-10
CY1118063T1 (el) 2017-06-28
EP1592777A4 (en) 2008-06-04
JP4764334B2 (ja) 2011-08-31
US20140295494A1 (en) 2014-10-02
AU2004209638A1 (en) 2004-08-19
CN102993306B (zh) 2015-01-28
EP2407485B1 (en) 2016-01-27
US20110064725A1 (en) 2011-03-17
US20060251644A1 (en) 2006-11-09
US7531169B2 (en) 2009-05-12
HUE028458T2 (en) 2016-12-28
US20130052202A1 (en) 2013-02-28
CN1771338A (zh) 2006-05-10
US9156908B2 (en) 2015-10-13
JP5296138B2 (ja) 2013-09-25
JP2011042654A (ja) 2011-03-03
DK2000481T3 (en) 2016-06-06
ES2575547T3 (es) 2016-06-29
CA2514840A1 (en) 2004-08-19
WO2004070011A2 (en) 2004-08-19
HUE028407T2 (hu) 2016-12-28
HK1126788A1 (en) 2009-09-11
WO2004070010A2 (en) 2004-08-19
CN102993306A (zh) 2013-03-27
AU2011202021B2 (en) 2013-08-29
CA2514840C (en) 2017-11-07
CN1771338B (zh) 2012-10-17
JP2006516408A (ja) 2006-07-06
EP2000481A1 (en) 2008-12-10
SI2000481T1 (sl) 2016-08-31
AU2011202021A1 (en) 2011-05-26
ES2566778T3 (es) 2016-04-15
DK2407485T3 (en) 2016-03-21
MX338940B (es) 2016-05-06
HK1085771A1 (en) 2006-09-01
AU2004209638B2 (en) 2011-02-03
CY1117617T1 (el) 2017-04-26
PT2000481E (pt) 2016-06-17
AU2004209637A1 (en) 2004-08-19
EP2000481B1 (en) 2016-03-30
CA2514839A1 (en) 2004-08-19
IL176940A (en) 2015-11-30
JP2006516409A (ja) 2006-07-06
EP1592776A4 (en) 2008-06-04
WO2004070011A3 (en) 2005-11-24
EP1592777A2 (en) 2005-11-09
EP1592776A2 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
CN1829806A (zh) 产生高亲和力抗体的方法
CN1246335C (zh) 用于治疗il－18介导疾病的重组il－18拮抗物
CN1105728C (zh) 用于治疗il4介导疾病的重组il4抗体
CN1211123C (zh) 抗白细胞粘附分子vla－4的人源化抗体
CN1305905C (zh) 人源化抗体及其制备方法
CN1241944C (zh) 抗人白介素－5受体α链的抗体
CN1077991A (zh) 具有人属性的抗人白细胞介素-5的单克隆抗体的设计，克隆和表达
CN1688338A (zh) 对免疫系统分子进行人源化的方法
CN1087681A (zh) 具有抗人体内病原菌感染的被动免疫力的新抗体
CN1662556A (zh) 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1656122A (zh) 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
CN1878790A (zh) 可中和的hgf表位和与其结合的中和抗体
CN1173878A (zh) 双功能或双价抗体片段类似物
CN1878793A (zh) 拮抗hmgb1的单克隆抗体
CN1407993A (zh) 基因重组抗体及其抗体片段
CN101052654A (zh) 具有改变的效应子功能的多肽变体
CN1541224A (zh) 拮抗性抗-hTNFSF13b人抗体
CN1283662C (zh) 拮抗性抗hFAS配基人类抗体及其片段
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN1551783A (zh) 治疗多发性骨髓瘤的方法
CN1254487C (zh) 抗免疫球蛋白等模式标本的重整形单克隆抗体
CN1310947C (zh) γ－1和γ－3抗人CD23单克隆抗体及其作为治疗剂的用途
CN1878792A (zh) Nogo－a结合分子及其药物用途
HK1093532A (en) A method for generating high affinity antibodies
CN1735629A (zh) 针对肿瘤坏死因子－α的单结构域抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093532

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060906

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1093532

Country of ref document: HK